Actively Recruiting
DCM Anti-Heart Antibody Diagnostic Kit Study Assessment of the Prognostic Impact of Anti-beta1AR and Anti-L-CaC Antibodies in Patients With Dilated Cardiomyopathy
Led by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Updated on 2025-04-11
1000
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are conducting a multicenter, prospective cohort study to understand the role of autoimmune reactions, specifically anti-beta1 adrenergic receptor (anti-β1AR) and anti-L-type calcium channel (anti-L-CaC) antibodies, in patients with dilated cardiomyopathy (DCM). The study aims to accurately evaluate how these antibodies relate to the prognosis of DCM, including risks such as cardiovascular death, ventricular tachycardia, and sudden death. This research will provide valuable epidemiological data and potential targets for future treatments for DCM. This study will follow 1,000 patients diagnosed with DCM across several centers in China for a period of three years. It focuses on measuring the prognostic value of these specific antibodies through regular assessments. Participants will be monitored for key health events such as all-cause death, heart transplantation, and rehospitalization for heart failure at multiple time points over the study period. During the study, participants will be followed up at months 1, 6, 12, 18, 24, and 36 to track clinical outcomes including death, heart transplant, heart failure rehospitalization, and sudden death. The study will gather detailed clinical information to assess the predictive value of the anti-β1AR and anti-L-CaC antibodies in DCM progression and outcomes. This observational approach allows researchers to closely monitor the natural course of the disease and antibody impact over time.
CONDITIONS
Brief Title
Evaluating the Prognostic Impact of Anti-β1AR Antibodies and Anti-L-CaC Antibodies in Patients With Dilated Cardiomyopathy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 18 and 75 years
- Diagnosed with dilated cardiomyopathy
- Fully informed about the study and voluntarily agree to participate by signing consent
You will not qualify if you...
- Serious uncontrolled infection at enrollment
- Uncontrolled active bleeding at enrollment
- Pregnancy or breastfeeding
- Serious diseases affecting survival, such as tumors with life expectancy under one year
- Previous heart transplant or cardiac assist device implantation
- Poor compliance preventing completion of the study
- Conditions that may increase risk or interfere with study results, including cognitive impairment, mental illness, or substance abuse
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 1 day
Participants undergo antibody testing to assess prognostic markers related to dilated cardiomyopathy.
1 visit (in-person)
Duration - 36 months
Participants are monitored for clinical outcomes including death, heart transplantation, and heart failure rehospitalization over 36 months.
Assessments at months 1, 6, 12, 18, 24, and 36
Trial Site Locations
Total: 1 location
1
Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China
Wuhan, Hubei, China, 430000
Actively Recruiting
Research Team
J
Jing Yuan
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here